Photo from Nitin Jain/X
May 17, 2024, 15:32
Nitin Jain: Looking forward to frontline Rx for patients with CLL at EHA2024
Nitin Jain, Professor of Medicine in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, shared a post on X:
“Looking forward to presenting investigator initiated phase 2 trial of time-limited pirtobrutinib + venetoclax + obinutuzumab as frontline Rx for patients with CLL at European Hematology Association 2024.”
Read further.
Source: Nitin Jain/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 15, 2025, 18:31
Jan 15, 2025, 18:25
Jan 15, 2025, 18:19
Jan 15, 2025, 17:48
Jan 15, 2025, 17:33
Jan 15, 2025, 17:27
Jan 15, 2025, 17:26
Jan 15, 2025, 17:19